Abstract 987TiP
Background
EU307 is an innovative anti-GPC3 CAR-T cell therapy developed specifically for treating GPC3-positive advanced hepatocellular carcinoma. GPC3, which is prominently expressed in HCC, represents a promising target for CAR-T cell therapy. However, the efficacy of CAR-T cell therapy in solid tumors like HCC is hindered by challenges such as identifying targetable antigens and overcoming the immunosuppressive tumor microenvironment. To address these challenges, EU307, as a fourth-generation CAR-T therapy, incorporates genetic engineering to secrete Interleukin-18 (IL-18), thereby enhancing CAR-T cell persistence and function within the solid tumor environment while specifically targeting the HCC-specific tumor antigen GPC3. This dual action stimulates autocrine co-stimulation of CAR-T cells and leads to the reprogramming of the tumor microenvironment into an environment conducive to tumor eradication.
Trial design
This is the first-in-human, open-label, multicenter Phase 1 dose-escalation trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of EU307. Eligibility criteria include patients with GPC3-positive advanced hepatocellular carcinoma who have failed standard therapy. Patients undergo lymphodepletion with cyclophosphamide and fludarabine before receiving EU307 CAR-T cell infusion. The starting dose of 1.0 x 10ˆ8 cells was determined based on the minimally anticipated biological effect level and pharmacologically active dose evaluation in non-clinical conditions. The primary objective is to assess safety through the evaluation of dose-limiting toxicities (DLT) and adverse events, and to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Secondary objectives include evaluating preliminary efficacy using mRECIST criteria, and exploring the pharmacokinetic properties of EU307 and changes in immune cells. The study is currently underway at four institutions in South Korea, with enrollment of the first participant in September 2023 and recruitment expected to be completed by 2024.
Clinical trial identification
NCT05783570.
Editorial acknowledgement
Legal entity responsible for the study
Eutilex Co., Ltd.
Funding
Eutilex Co., Ltd.
Disclosure
H. Park, Y. Choi: Financial Interests, Institutional, Full or part-time Employment: Eutilex. Co., Ltd. Y. Chang: Financial Interests, Institutional, Full or part-time Employment: Eutilex Co., Ltd; Financial Interests, Institutional, Stocks/Shares: Eutilex Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
983P - Updated safety and efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a phase I study
Presenter: Xiao-Ping Chen
Session: Poster session 17
984P - Regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: Interim results from the multicenter real-world study
Presenter: Jian Lu
Session: Poster session 17
Resources:
Abstract
985P - Analysis of antidrug antibodies (ADA) to camrelizumab in CARES-310: The pivotal phase III study of camrelizumab + rivoceranib in unresectable hepatocellular carcinoma (uHCC)
Presenter: Ahmed Kaseb
Session: Poster session 17
1150P - Search for biomarkers to personalize treatment with streptozotocin plus 5-fluorouracil or everolimus in patients with advanced pancreatic neuroendocrine tumors: The randomized phase III SEQTOR trial (GETNE-1206)
Presenter: Ramon Salazar Soler
Session: Poster session 17
1151P - Biochemical and radiological efficacy of systmic lanreotide therapy of patients with advanced, unresectable, non-metastatic paraganglioma/pheochromocytoma (PPGL) sporadic and hereditary
Presenter: Agnieszka Kolasińska-Ćwikła
Session: Poster session 17
1152P - Correlation of biochemical secretion and imaging parameters on [18F]-SiTATE-PET/CT in pheochromocytoma and paraganglioma
Presenter: Meike Onkes
Session: Poster session 17
1153P - Preclinical characterization of MC339: A novel radiotherapeutic agent for DLL3 expressing cancers
Presenter: Anneli Savinainen
Session: Poster session 17
1154P - Prospective multinational evaluation of alkylating-induced hypermutation in neuroendocrine neoplasms (NEN): Clinical and molecular profiles associated with response to immune checkpoint inhibitors (CPI)
Presenter: Elena Trevisani
Session: Poster session 17